NASDAQ:ENTX

Entera Bio Stock News

Healthcare > Biotechnology

Buy ENTX

*Your capital is at risk

$1.22

-0.0300 (-2.40%)

At Close: Jun 03, 2026

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

10:11am, Tuesday, 09'th Apr 2024

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

08:30am, Monday, 08'th Apr 2024

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data fr

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

08:30am, Tuesday, 26'th Mar 2024

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The Ame

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

08:00am, Wednesday, 20'th Mar 2024

JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pha

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

04:05pm, Friday, 08'th Mar 2024

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial res

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

08:30am, Monday, 04'th Mar 2024

JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it rece

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

08:30am, Tuesday, 30'th Jan 2024

JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, anno

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

08:00am, Wednesday, 03'rd Jan 2024

JERUSALEM, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, anno

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

08:00am, Tuesday, 26'th Dec 2023

JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, anno

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

08:30am, Wednesday, 29'th Nov 2023

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, repo

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

07:30am, Tuesday, 14'th Nov 2023

JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic protein

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

02:30pm, Thursday, 09'th Nov 2023

JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, repo

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

08:30am, Wednesday, 16'th Aug 2023

JERUSALEM, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, toda

Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates

06:57pm, Friday, 05'th May 2023

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12.

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

06:22pm, Friday, 31'st Mar 2023

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by